CHAPTER I INTRODUCTION

General Introduction
Malaria is caused by a parasite carried by mosquitos, and has represented a global health problem for humans throughout history. More than 40% of the population worldwide is at risk of contracting malaria. The World Health Organization reported in 2010 that the 219 million cases of malaria resulted 660 thousand deaths [1] . The majority of fatalities were children under the age of five. In 2015, the World Health Organization reported 212 million cases leading to 429 thousand deaths, with 303 thousand being children under five years of age [2] . Although substantial progress was made from 2010 to 2015 in reducing deaths (child-death due to malaria decreased by 29%), malaria kills children in Africa at a rate of one for every two minutes. The most common treatment for malaria is artemisinin and its derivatives, but in 2005 resistance to artemisinin by Plasmodium falciparum, the most common causative agent of malaria in humans, emerged in Southeast Asia (specifically, five countries in the Greater Mekong sub-region) [2] .
Resistant strains of the pathogen will spread worldwide, threatening recent progress made toward eradicating the disease. New drugs will be necessary in order to meet the goal of disease eradication by 2030.
Five species of Plasmodium cause malaria in humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium knowlesi. The first four are transmitted to humans by mosquitoes, the last through contaminated water [3] . P. falciparum represents the largest threat to human health, causing 99% of the 429 thousand deaths due to Plasmodium infections [2] . After transmission from mosquito to human, the parasite (sporozoites stage) infects liver cells and undergoes replication [4] . After one cycle of replication, the infected liver cell (liver schizont) bursts, releasing merozoites that infect red blood cells. Merozoites replicate in the red blood cell, forming after 48 hours a red blood cell shizont, which bursts releasing more merozoites into the blood stream. The destruction of red blood cells and release of merozoites cause symptomatic peaks of fever and anemia associated with malaria [5] . Some merozoites mature to the gametocyte stage. Subsequent mosquito predation results in the transfer of gametocytes from human to the gut of the mosquito, where gametocytes develop into first microgametes, then macrogametes and finally zygotes. Zygotes migrate out of the mosquito gut, develop into oocysts, which burst and release sporozoites ready for infection of a human (or another mammalian) host.
Plasmodium species are members of the phylum Apicomplexa [5] . Most apicomplexans have a four-membrane plastid called the apicoplast. Genetic analysis supports the evolution of the apicoplast from the chloroplast of red algae. Putatively, a secondary endosymbiotic event resulted in the capture of red algae by a primordial predecessor of Plasmodium [6] . Over time, the captured chloroplast lost its photosynthetic capabilities, but retained (or acquired) and evolved metabolic pathways for fatty acid, isoprenoid and heme synthesis, as well as Fe-S cluster maturation. The apicoplast is essential for the replication of the parasite. Daughter merozoites without apicoplast do not undergo further cell division. In fact, loss of the apicoplast results in the "delayed-death" of the parasite in both the liver and red-blood cell stage of an infection [7] . The parasite survives but daughter cells are unable to sustain an infection. Because of its presence in a single phylum (which includes many organisms responsible for infectious disease) and because of its essential role in sustaining parasite reproduction, the apicoplast is a potential target in the development of anti-malarial drugs [7] .
Approximately 600 proteins reside within the apicoplast. Eight percent are involved in translation, 1% in transcription and 4% in DNA replication. Inhibition of DNA polymerases has led to effective treatments of HIV, herpes simplex virus, hepatitis B virus, and cytomegalovirus [8] . Hence, inhibition of the DNA polymerase responsible for the duplication of the genome of the apicoplast seems a reasonable strategy. Replication of the apicoplast genome involves a DNA polymerase, helicase, primase, single-stranded DNA binding protein, DNA gyrase and ligase. All are promising targets for the development of anti-malarial drugs. In fact, ciprofloxacin, an inhibitor of the apicoplast topoisomerase (gyrase), has anti-malaria activity [9] .
PfPREX (Plasmodium falciparum plastidic DNA replication/repair enzyme complex) is a polyprotein translated in the cytoplasm of Plasmodium and imported to the apicoplast. PfPREX is 235 kDa and contains concatenated sequences similar to a DNA primase, helicase and polymerase separated by spacers [10] . PfPREX, N-terminally labeled with green fluorescent protein, accumulates in the apicoplast of P. falciparum [10] . Moreover, as the polymerase and primase subunits of PfPREX have no direct orthologues in mammalian cells, these authors maintain that these two enzymes might be fruitful targets in the development of new drugs. The DNA polymerase component of PfPREX, hereafter called apPOL, bears low sequence identity (20-30%) to A-family DNA polymerases found in the thermophilic bacteria of the phylum Aquificae and to the Klenow fragment of Escherichia coli [11] [12] . The nearest homolog outside Apicomplexa is the cyanobacteria Cyanothece sp. PCC 8802 replication polymerase (35% sequence identity) [13] . Of all polymerases in humans, the nearest to apPOL is the lesion bypass polymerase theta with 23% identity and nu with 22% identity. As the apicoplast DNA polymerases of P. vivax and P. falciparum are 84% identical [14] , an effective drug against P. falciparum might be effective against all strains of Plasmodium that infect humans.
A-Family polymerases, of which apPOL is an example, come predominantly from bacteria, but also from mitochondria, the nucleus of eukaryotes and some bacteriophage [15] .
Bacterial DNA polymerases often elongate Okazaki fragments, remove RNA primers during replication, and repair DNA. Such polymerases employ a 5ʹ to 3ʹ polymerase domain, a 3ʹ to 5ʹ exonuclease proofreading domain, and a 5ʹ to 3ʹ exonuclease domain for primer removal and DNA repair [15, 16] . Structures of A-family polymerases are available for the Klenow fragment from Escherichia coli Polymerase I (Klenow), the large fragment of the DNA polymerase from Bacillus stearothermophilus (BF), and the DNA polymerases from bacteriophage T7 (T7), Thermus aquaticus (Taq), and mitochondria (DNA pol ) [17] [18] [19] , as well as two low-fidelity eukaryotic A-family polymerases that reside in the nucleus [20] [21] . Each resembles a right hand with finger, palm, and thumb subdomains [ Figure 1 ]. The palm subdomain is well-conserved, whereas the finger and thumb subdomains diverge across species [22] . The 3ʹ to 5ʹ exonuclease domains are poorly conserved except for three amino acid motifs at or near the exonuclease active site [23] .
Although crystal structures are available, the reproducible growth of suitable crystals and the successful cryoprotection of crystals for data collection represent major challenges. Nterminal polyhistidyl-tagged apPOL provided only small crystals (<5 µm), and only 1 in 300 crystals provided usable X-ray diffraction data after freezing in liquid nitrogen [24] . C-terminal polyhistidyl-tagged apPOL provides non-twinned crystals of size 20 µm that more readily retain crystalline order upon freezing [24] ; however, the production of two crystal structures in as many years is an unfavorable rate of progress when confronted with the prospect of investigating several hundred polymerase-inhibitor complexes in the context of a drug discovery effort. The 
Introduction
Malaria is a common disease carried by mosquitos. Based on the World Health Organization, malaria causes about 200 million infections and 429,000 deaths in 2015 [1] . About ¾ of all deaths are of children 5 years of age and younger. About 40% of the world population is living at risk of malaria, especially those in Africa and Southeast Asia. Increased resistance to anti-malarial drugs has emerged in central Africa, India, Southeast Asia and South America. [1] In humans, Plasmodium falciparum is the leading cause of malarial infections. In the 2016 World Malaria Report, 99% of the 429 thousand deaths in 2015 are caused by P. falciparum [1] . P. falciparum is a member of phylum Apicomplexa [2] . Most organisms in Apicomplexa have a four-membrane organelle called the apicoplast, which is thought to be evolved from the secondary endosymbiosis of the chloroplast of red algae [3] . The apicoplast has its own genome and is involved in fatty acid biosynthesis, isoprenoid synthesis, heme synthesis, and Fe-S cluster maturation. Loss of the apicoplast results in a "delayed death" phenotype in which the daughter cells that lack apicoplasts are nonviable [4] . Thus, the biochemical system responsible for apicoplast reproduction is a target for the development of new antimalarial drugs.
Approximately 600 proteins reside within the apicoplast and around 8% are involved in translation, 1% in transcription, 3% in DNA replication. Research shows [5] [6] [7] that a Type A family DNA polymerase (apPOL) is imported to the apicoplast and used in the replication of its genome. The nearest A-family homolog of apPOL outside of the phylum Apicomplexa is the replication polymerase from the cyanobacteria Cyanothece sp. PCC 8802 (35% sequence identity) [8] . In humans, there are three Type A family polymerases, the nearest to apPOL is the lesion bypass polymerase theta with 23% identity and nu with 22% identity. On the other hand, apPOL is 84% sequence-identical to the apicoplast DNA polymerase of Plasmodium vivax [9] .
Drugs effective against apPOL from P. falciparum might also work against other causative agents for malaria.
Although crystal structures are available, the reproducible growth of suitable crystals and the successful cryoprotection of crystals for data collection represent major challenges. Nterminal polyhistidyl-tagged apPOL provided only small crystals (<5 µm), and only 1 in 300 crystals provided usable X-ray diffraction data after freezing in liquid nitrogen [10] . C-terminal polyhistidyl-tagged apPOL provides non-twinned crystals of size 20 µm that more readily retain crystalline order upon freezing [11] ; however, the production of two crystal structures in as many years is an unfavorable rate of progress when confronted with the prospect of investigating several hundred polymerase-inhibitor complexes in the context of a drug discovery effort. The purpose of experimental work here is the determination of conditions that (i) lead to the rapid, 
Mutation of exonuclease-inactive (apPOL exo− ) into wildtype polymerase (apPOL).
apPOL exo− , which has a double mutation to its exonuclease active site (D82N and E84Q), was the basis of kinetics and structural work on apPOL [11] [12] . Work here employed wild-type apPOL, obtained by Quickchange [BIO-RAD] mutagenesis of the plasmid for apPOL exo− (E. coli pet28b)
into wild-type apPOL [10] . The forward primer sequence used in mutagenesis was 5'-
(N82D/Q84E) where the codons responsible for mutation in bold typeface. The reverse primer sequence was the reverse complement of the forward primer. The mutations were confirmed by sequencing the DNA of the final construct at the Iowa State University DNA Facility.
Protein expression and purification. E. coli BL21 cells were transformed with the plasmid (E. coli pet28b) containing the insert for the wild-type DNA polymerase from the apicoplast of P. falciparum with a C-terminal polyhistidyl tag. After incubation at 37 ℃, a single colony was picked from an LB/kanamycin agar plate, and then used in the inoculation of 200 mL LB medium with kanamycin (30 µg/mL). After modest shaking for 16 hrs. at 37 ℃, 10 mL aliquots of the overnight culture were added to 1 L flasks containing 800 mL of LB with kanamycin (30 µg/mL). Flasks were incubated at 37 ℃ with shaking (225 rpm) until A 600 reached 0.6. Flasks were cooled to 18 ℃ by transfer to a cold room, after which isopropyl 1-thiob-D-galactopyranoside was added to a concentration of 0.2 mM. After an additional 16 hrs. with shaking (225 rpm) at 18 ℃, cells were collected by centrifugation at 4000 rpm for 30 minutes.
The cell pellet was re-suspended in 20 mM Tris-HCl, 500 mM NaCl and 5 mM imidazole, pH 8.0 and passed through an EmulsiFlex-C3 homogenizer at least 3 times at 30,000 psi. The cell lysate was centrifuged at 17000 rpm at 4℃ for 50 minutes.
The supernatant loaded onto a 3 mL Ni-NTA-agarose column. The column was washed with 100 mL of 20 mM Tris-HCl, 500 mM NaCl and 5 mM imidazole, pH processed by HKL-3000, using a cutoff on spurious negative intensities (sigma cutoff -1) and using a resolution cut-off that retained data up to and including a high-resolution shell with <I>/<sigma-I> of ~1. Experience in the refinement of previous structures of apPOL [11] indicated data to a resolution of <I>/sigma<I> of 0. 
Results
The protein is abundant in the cell-free extract ( Fig. 1 ) and was at least 95% pure after size exclusion chromatography (Fig. 2) . Results of data collection and refinement appear in Table   1 . All crystals dipped in DMSO and MPD provided data in the resolution range of 3.0 to 3.5 Å, and behaved comparably in refinement. Crystals dipped in t-butanol and acetonitrile either exhibited no diffraction (acetonitrile) or very poor diffraction (t-butanol) ( Table. 2). Efforts here focus on crystals exposed to MDP and DMSO.
Sulfate anions and their binding sites on apPOL appear in Table 3 and Fig. 3 . The identification of sulfate anions benefitted from the crystal structure PDBID:5DKU, which lacked sulfate, Li + , and organic small molecules. The majority of sites in Table 3 appear in both molecules of apPOL in the asymmetric unit. On the basis of crystallographic criteria alone, sulfate anion binding is most robust at Site-701 (Fig. 3) After the initial round of refinement, crystals grown in the presence of the Li + exhibited significant electron density and difference electron density in a void separating the two polymerase molecules in the asymmetric unit of the crystal (Fig. 4) . The centroids of these spheres of electron density were far (>3. The region has several residues with either positive or negative electrostatic charge (Asp240 A&B, Asp 561 A&B, Lys 244 A&B) with a net overall charge that is negative. Electron density spheres of the kind observed in structures which included Li + , were absent in structures that excluded the lithium cation from the crystallization conditions. Given these observations, we assigned hydrated Li + complexes to each of the spheres. 6 ] + , appears in Fig. 5 . Hydrogen-bonding residues in proximity to each complex cation are given in Table 4 . All sites assigned to a complex lithium cation are between the two molecules in the asymmetric unit (Fig. 6 ). In PDBID:5DKU the same region exhibits difference electron density, consistent with disorganized water. In the MES/DMSO/Ca 2+ complex (sulfate present), low electron difference density in this intermolecular space eliminates sulfate as a contributing factor.
Indeed, one would not expect a sulfate binding side juxtaposed to acidic side chains of aspartate as documented in Table 4 .
Crystals exposed to DMSO exhibited diffraction to a resolution comparable to crystals exposed to MPD or no organic solvent, but then decayed rapidly in the X-ray beam, limiting the amount of useable data ( Table 2) . We would hope to see an effect due to DMSO on lattice contacts in the crystals or on the polymerase, and in fact, we observe a consistent conformational change in the polymerase when DMSO is present (MES/DMSO/Ca 2+ and MES/DMSO/Li + ). In all structures determined from crystals exposed to DMSO the side chain of Trp512 has rotated out of the hydrophobic core of the polymerase domain into the solvent (Fig. 7) , and a ball of 
Discussion
The sulfate anion at Site-701 is likely associated with some functional aspect of the polymerase. If sites of lower occupancy (and arguably lower affinity for sulfate) represent binding sites for phosphoryl groups of the substrate (dNTP) or primer/template DNA, then the highest affinity site for sulfate is not likely an artifact of crystallography. Most notably, if one extends the template strand at its 5'-end relative to the 3'-end of the primer, the second additional phosphodiester linkage could reach sulfate Site-701 when the primer/template DNA is in the putative editing mode of the polymerase (Fig. 10 ). This hypothetical role for Site-701 as a recognition site for template DNA when primer DNA occupies the exonuclease site could be tested by mutation. Elimination of Site-1 through the introduction of a bulky side chain can be verified by a crystal structure determination. The anticipated impact on polymerase function would be the loss of pause-edit kinetics and/or a significant loss in polymerase fidelity. This site could also be of interest in the development of drugs that impact P. falciparum replication by compromising the genomic "health" of the apicoplast. We prefer the latter interpretation, on the basis of electron difference density, which is enhanced whenever Li + is part of the crystallization medium. When Li + is absent the low electron density between polymerase molecules is due to quasi-organized water molecules.
Given that a single Li + influences 13 
Tables
P2-13 Li/t-Butanol - - - - - - weak diffraction P3-5 Li/t-Butanol - - - - - - weak diffraction P3-6 Li/t-Butanol - - - - - - weak diffraction P1-7 Li/Acetoniti le - - - - - - disordered P1-8 Li/Acetoniti le - - - - - - disordered P2-15 Li/Acetoniti le - - - - - - disordered P2-16 Li/Acetoniti le - - - - - - disordered✔ ✔ ✔ ✔ ✔ ✔ ✔ 702 Trp199 NE1 ✔ ✕ ✕ ✕ ✕ ✕ ✕ 703 Leu178 NH, Gln138NE2, Asn139ND2 ✔ ✕ ✕ ✔ ✔ ✔ ✔ 704 Gln387 NE2 ✔ ✔ ✕ ✔ ✔ ✔ ✔ 705 Ser375 NH, Phe374 NH ✔ ✔ ✔ ✔ ✔ ✔ ✔ 706 Lys382 NH, Asn384 NH, Lys 352 NZ ✔ ✔ ✕ ✔ ✔ ✔ ✔ 707 Lys511 NZ, Asn424ND2 ✔ ✔ ✔ ✔ ✔ ✔ ✔ 708 His236 N, Ile237 N, Asn 234 ND2 ✔ ✕ ✕ ✕ ✕ ✕ ✕ 709 Lys171 NZ, Lys 169 NZ ✔ ✕ ✔ ✕ ✔ ✕ ✔ 710 Arg459 NH1, NH2 ✕ ✔ ✔ ✔ ✔ ✔ ✔ 711 Arg520 NH1, NH2 ✕ ✔ ✔ ✔ ✔ ✔ ✔ 712 Ser538 OG, Lys448 NZ ✕ ✔ ✔ ✔ ✔ ✔ ✔ 713 Lys463 NZ, His460 ND ✕ ✕ ✔ ✕ ✔ ✕ ✔ 714 Lys531A NZ, Asn433BND2, Asn234 B ND2 ✕ ✕ ✔ ✔ ✔ ✔ ✔ 715 Lys192 NZ ✕ ✔ ✕ ✔ ✔ ✔ ✔ 716 Asn435 * ND2, Lys171 NZ, Lys184 NZ ✕ ✔ ✔ ✔ ✔ ✔ ✔ 717 HIS439 NE, Gln413 NE2 ✕ ✕ ✕ ✔ ✕ ✔ ✕ 718 Lys153 NZ, ✕ ✕ ✕ ✔ ✔ ✔ ✔ *✕ ✕ ✕ ✔ ✔ ✕ ✕ 731 Asp240 ✕ ✕ ✕ ✔ ✔ ✔ ✔ 732 Asp561 ✕ ✕ ✕ ✔ ✔ ✔ ✔
CHAPTER III CONLUSIONS
Summary
The primary contribution to drug development efforts of the work presented here comes from the discovery of the lithium cation as an agent of enhanced crystal growth. In the first three years of crystallographic work only two usable data sets resulted from well over 1000 crystals mounted and probed by X-ray diffraction. Over the past year, more than 20 data sets have been collected. In the presence of Li + , crystals grow faster and larger than in the absence of 
Further Study
We are planning to determine whether MPD is a cryo-protectant by comparing diffraction from crystals of apPOL, with and without MPD, frozen in liquid nitrogen. Beside this, we are also interested in Site 701, which by hypothesis is a recognition site for template DNA when primer DNA occupies the exonuclease site. The introduction of a residue with a β-branched sidechain, or one of negative charge by site-directed mutation should block sulfate binding. Crystal structures of the mutant in the presence of sulfate would confirm the success of the mutation, and experiments in kinetics will test whether this primary site for sulfate binding plays the proposed functional role in locking the template DNA into a conformation that stabilizes the pause-edit action of the polymerase.
